PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
13-Jan-2025 Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer Outrun Therapeutics
13-Jan-2025 CNX Therapeutics expands European CNS portfolio with licensing agreement for Sumatriptan Alginate Film CNX Therapeutics
13-Jan-2025 Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Sanofi
13-Jan-2025 Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel Teva Pharmaceuticals
13-Jan-2025 GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITH POTENTIAL IN MULTIPLE INFLAMMATORY DISEASES Gilead Sciences, Inc.
13-Jan-2025 Frontage Announces Co-CEO Promotions Frontage Holdings Corporation
13-Jan-2025 Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology Medtronic
13-Jan-2025 Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone Novavax
13-Jan-2025 Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement Eckert & Ziegler SE
13-Jan-2025 Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma Heidelberg Pharma AG
13-Jan-2025 Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel Formycon AG
10-Jan-2025 iTeos Announces 2025 Strategic Priorities and Anticipated Milestones iTeos Therapeutics
10-Jan-2025 SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025 SYNBIOTIC SE
10-Jan-2025 Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology Synaffix B.V.
10-Jan-2025 Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics Oxford BioTherapeutics (OBT)
10-Jan-2025 Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology Boehringer Ingelheim
10-Jan-2025 PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) PureTech
10-Jan-2025 Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology Boehringer Ingelheim
10-Jan-2025 New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sanofi
10-Jan-2025 Labcorp and Inspira Health Announce Strategic Agreement for Lab Operations Labcorp